Baum Hedlund Aristei & Goldman P.c.
Recent News About Baum Hedlund Aristei & Goldman P.c. View More
-
GSK: Widow's request to restore $3M verdict in suicide suit would destabilize legal system
A drug company sued by the widow of a Chicago man, who killed himself after taking the generic form of the antidepressant Paxil, argues that the widow has launched a “frivolous," “topsy-turvy” and "unprecedented" effort to have a Chicago federal district judge override the U.S. Supreme Court and restore a $3 million verdict. -
SCOTUS gives win to GSK in appeal of $3M verdict over Chicago lawyer's suicide, Paxil drug labeling
The widow of a lawyer who took his own life, allegedly after taking the generic equivalent of widely prescribed antidepressant drug, Paxil, will not get a chance to undo a federal appeals court’s decision to toss out a federal jury’s findings that GSK, the maker of Paxil, owes her $3 million because it allegedly didn’t push federal regulators hard enough to revise the drug’s warning label. -
SCOTUS weighs competing briefs in widow's appeal in case vs GSK over suicide of lawyer taking generic Paxil
The U.S. Supreme Court is tackling the question of whether drug companies can be sued for not making their warning labels strong enough, even though the FDA controls the labels. But whether a forthcoming Supreme Court decision will affect a decision denying a $3 million judgment to the widow of a Chicago lawyer who committed suicide after taking the generic equivalent of Paxil remains unclear. -
Widow asks SCOTUS to toss GSK's win in lawsuit over Paxil labeling, lawyer's suicide
Asserting a Chicago federal appeals panel wrongly invalidated a jury’s verdict, attorneys for the widow of a Chicago lawyer who committed suicide after taking the generic version of the antidepressant drug Paxil, have asked the U.S. Supreme Court to throw out the appellate ruling and order more proceedings on whether pharmaceutical company GlaxoSmithKline should be made to pay for allegedly not revising their drug’s warning label to reflect an increased risk of suicide. -
Federal appeals court won’t review its decision to toss $3M verdict v. GSK; Plaintiff: ‘Dangerous precedent’
A Chicago federal appellate court has refused to reexamine its decision last month that reversed a $3 million verdict against drugmaker GlaxoSmithKline, on grounds the company was not responsible for the labeling of the generic version of its product Paxil, despite plaintiff’s urging a rehearing was needed, because she said the appeals panel set a “dangerous precedent.” -
Appeals court tosses $3M verdict vs GSK, says FDA, not drugmaker, controlled Paxil warning label
A federal appeals panel has tossed out a $3 million verdict vs GSK for the widow of a Chicago lawyer who committed suicide after taking the generic equivalent of GSK's drug, Paxil. The judges said the company can't be held responsible for language on the warning label when that language was controlled by the FDA. -
SCOTUS takes Merck's Fosamax appeal, could boost GSK's appeal of $3M verdict over lawyer's suicide
The U.S. Supreme Court has decided to wade into the contentious question over whether a pharmaceutical company can be held liable for failing to warn consumers and doctors of a drug’s potential effects, potentially portending significant implications for a $3 million verdict a jury awarded to the widow of a Chicago lawyer who committed suicide in the Loop after taking the generic version of an antidepressant drug. -
Appeal judges mull 'troubling' questions on potential fallout from $3M verdict vs GSK over lawyer's suicide
With one judge saying he found “troubling” the potential harm to patients from decreased incentives for drug makers to develop new breakthrough medications, a federal appellate panel in Chicago hashed out some of the legal questions surrounding the appeal of jury’s verdict ordering GlaxoSmithKline to pay $3 million to the widow of a Chicago lawyer who committed suicide, and whose family has accused the pharmaceutical company of failing to warn that a generic version of its drug Paxil could raise a patient’s risk of suicide. -
GSK appeals $3M verdict over lawyer's suicide, Paxil labeling
About two weeks after a Chicago federal judge turned down its request for a new trial, pharmaceutical maker GlaxoSmithKline has formally appealed the judicial decisions the company has contended led to a jury improperly awarding $3 million to the widow of a Chicago lawyer who committed suicide by stepping in front of a train in Chicago’s Loop after taking a generic version of Paxil, an antidepressant developed by GSK. -
Judge: No need for new trial, $3M verdict vs GSK over lawyer's suicide should stand
Pharmaceutical maker GlaxoSmithKline will not get a chance to undo a jury’s verdict, finding it owes $3 million to the widow of a Chicago lawyer who committed suicide, allegedly after taking a generic equivalent of GSK’s anti-depressant drug, Paxil. -
Label or Liability: Case law could lead to short shelf life for $3M Paxil 'innovator liability' verdict
A Chicago federal jury shocked many observers by ordering drugmaker GlaxoSmithKline to pay $3 million to the widow of lawyer Stewart Dolin, who committed suicide in 2010 after taking a generic version of GSK's antidepressant Paxil. But legal observers believe the decision may have a short shelf life, as it could defy decades of case law on the concept of innovator liability. -
GSK asks for new trial over claims its anti-depressant labeling contributed to lawyer's suicide
Drug manufacturer GlaxoSmithKline is trying to get out from under a $3 million jury judgment, which blamed it for a Chicago lawyer’s suicide, saying a federal judge made multiple mistakes that hamstrung the manufacturer’s defense against the claim its labels failed to warn its anti-depressant drug Paxil and its generic equivalent can lead to suicide. -
Jury: GSK liable for suicide of lawyer taking generic Paxil; $3M awarded to widow
A federal jury in Chicago has ordered pharmaceutical maker GlaxoSmithKline to pay $3 million to the widow of a Chicago lawyer who committed suicide by jumping in front of a train after taking a generic version of Paxil, an antidepressant developed by GSK, finding the drugmaker should be held responsible for his death, even though it didn’t make the actual medication the lawyer had been taking for about a week before he took his life. -
Judge denies request to end trial vs drugmaker GSK over suicide of lawyer taking generic Paxil
A trial continues this week in Chicago federal court over the question of how much blame should be shouldered by drugmaker GlaxoSmithKline for the death of a Chicago lawyer who committed suicide after taking a generic version of Paxil, an antidepressant developed by GSK. This week, a federal judge denied an attempt by GSK to abruptly end the weeks-long trial and secure a judgment in its favor. -
Trial set to begin in litigation vs drugmaker GSK over suicide by lawyer who took generic Paxil
This week, a Chicago federal court will empanel jurors to decide whether pharmaceutical maker GlaxoSmithKline should be made to pay the widow of a Chicago lawyer who committed suicide by jumping in front of a train after taking a generic version of Paxil, an antidepressant developed by GSK, because, the woman claims, the drug’s warning label, which was approved by federal regulators, did not contain enough information on suicide risk, misleading the doctor who prescribed it.